Lyra Therapeutics (LYRA) EBT Margin (2021 - 2025)
Lyra Therapeutics (LYRA) posted EBT Margin of 99271.43% for Q4 2025, down 314.94% on a QoQ basis from 23924.0% in Q3 2025, and down 9402119.0% year-over-year from N/an in Q4 2024.
Powered by 
Analysis
Lyra Therapeutics (LYRA) EBT Margin (2021 - 2025) Analysis & Trends
Lyra Therapeutics has reported EBT Margin for 5 years, with the latest figure at 99271.43% in Q4 2025.
- On a quarterly basis, EBT Margin fell 9402119.0% year-over-year to 99271.43% in Q4 2025; TTM through Dec 2025 was 7263.32%, a 117492.0% decrease from a year earlier, with the FY2025 full-year figure at 7263.32%, down 117492.0% from the prior year.
- EBT Margin was 99271.43% for Q4 2025 at Lyra Therapeutics, down from 23924.0% in the prior quarter.
- The five-year high for EBT Margin was 2545.09% in Q1 2022, with the low at 129290.91% in Q4 2022.
- Average EBT Margin over 5 years is 22156.26%, with a median of 4846.51% recorded in 2021.
- The sharpest annual moves came in 2022 and 2023: EBT Margin tumbled 12426619 bps in 2022, then surged 11892173 bps in 2023.
- Over 5 years, EBT Margin stood at 5024.72% in 2021, then plunged by 2473 bps to 129290.91% in 2022, then jumped by 92 bps to 10369.18% in 2023, then jumped by 49 bps to 5250.24% in 2024, then tumbled by 1791 bps to 99271.43% in 2025.
- The last three EBT Margin figures came in at 99271.43% (Q4 2025), 23924.0% (Q3 2025), and 4062.84% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Lyra Therapeutics | 354,976.41 | 354,976.41 | - | -99,271.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -99,271.43% |
| Sep 30, 2025 | -23,924.00% |
| Jun 30, 2025 | -4,062.84% |
| Mar 31, 2025 | -4,668.31% |
| Dec 31, 2024 | -5,250.24% |
| Sep 30, 2024 | -6,085.13% |
| Jun 30, 2024 | -8,046.66% |
| Mar 31, 2024 | -4,217.67% |
| Dec 31, 2023 | -10,369.18% |
| Sep 30, 2023 | -2,874.08% |
| Jun 30, 2023 | -3,407.42% |
| Mar 31, 2023 | -3,961.22% |
| Dec 31, 2022 | -129,290.91% |
| Sep 30, 2022 | -4,113.09% |
| Jun 30, 2022 | -2,736.38% |
| Mar 31, 2022 | -2,545.09% |
| Dec 31, 2021 | -5,024.72% |
| Sep 30, 2021 | -78,964.29% |